Beta blocking drugs as anti-arrhythmic agents.
Fifteen years after the introduction of beta adrenergic blocking drugs into clinical medicine, there is satisfactory evidence indicating that this class of drug has significant anti-arrhythmic activity. The chief indications for using these drugs are for the control of sinus tachycardia digitalis dysrhythmias and for the control of rapid ventricular rates atrial and ventricular dysrhythmias. The mode of action is by antagonizing the cardiac actions of catecholamines on cardiac automaticity and conduction.
D000200:Action Potentials / Q000187:drug effects; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001001:Anura; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D004285:Dogs; D004553:Electric Conductivity / Q000187:drug effects; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011817:Rabbits; D013610:Tachycardia / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D011217:Practolol